Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Inclusion Criteria:

- Subjects of either gender aged ≥ 50 years

- All flourescein angiographic subtypes with presence of active choroidal
neovascularization

Exclusion Criteria:

- Any intraocular surgery or thermal laser within three (3) months of trial entry. Any
prior thermal laser in the macular region, regardless of indication

- Subjects with subfoveal scar or subfoveal atrophy

- Any ocular or periocular infection in the past twelve (12) weeks

- History of any of the following conditions or procedures in the study eye:
Rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery (e.g.
trabeculectomy), glaucoma drainage device, corneal transplant